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Going for the Trunk
BY NICHOLAS NORWITZ ’18
Summary
Although angiogenesis (new blood vessel 
formation) is an absolute requirement for tumor 
growth, therapies designed to treat cancer 
by targeting specific angiogenic factors have 
had limited success. One theory is that there 
are many different angiogenic factors that 
can compensate for the loss of a single factor. 
Therefore, a more effective strategy may be to 
move upstream, identify a factor that regulates 
the expression of many different downstream 
angiogenic mediators, and then measure the 
effect of blocking this single common factor on 
angiogenesis-mediated tumor growth.
What is Angiogenesis?
In 1971, Dr. Judah Folkman observed 
that, without new blood vessel formation, 
tumors arrest at a threshold size of 2-3mm 
(Folkman, 1971; Hanahan and Weinberg, 2000). 
Folkman also discovered that tumors release an 
angiogenic promoting paracrine factor, which 
he called tumor-angiogenesis factor (TAF), and 
hypothesized that blocking TAF signaling might 
serve as an effective cancer therapy (Folkman, 
1971). 
As angiogenesis is regulated by a balance 
between pro-and anti-angiogenic molecules, 
the basis of Folkman’s hypothesis was sound. 
Therapies that shift the balance away from pro-
angiogenic signals will impair tumor growth. 
However, the problem is more complicated. 
Scientists have discovered an abundance of 
pro-angiogenic factors, including vascular 
endothelial growth factor (VEGF), epidermal 
growth factors (EGFs), transforming growth 
factors (TGFs), tumor necrosis factor (TNF), 
fibroblast growth factors (FGFs), platelet-derived 
growth factor (PDGF), hepatocyte growth factor 
(HGF), angiopoietins, and various chemokines 
(Ferrara, 2002; Bouis et al., 2006). 
While different tumors promote angiogenesis 
by relying on different combinations of these 
factors, it is possible to develop therapies that 
effectively block angiogenesis by targeting 
specific angiogenic molecules (Fernando et al., 
2008; Casanovas et al., 2005; Kopetz et al., 2010). 
The most studied angiogenic factor is VEGF. 
Many different approaches have been developed 
to target VEGF signaling including monoclonal 
antibodies and receptor blockers. While many 
of these therapies are initially effective, tumors 
are soon able to compensate by up-regulating 
other pro-angiogenic factors and overcoming 
this angiogenic blockade (Casanovas et al., 2005; 
Kopetz et al., 2010).
Modern Attempts to Inhibit 
Angiogenesis
Modern medicine has been trying to kill 
the cancer tree by chopping at the ends of its 
thinnest branches, and this strategy has had 
only limited success. The cancer simply learns 
to rely on other branches in order to grow. 
The work of Dr. Anil Sood et al. published in 
Nature in February 2016, concentrates on a new 
approach that is fundamentally different from 
previous therapies in that it emphasizes choking 
the cancer tree by chopping closer to the trunk. 
By identifying and targeting the molecular fork 
from which many angiogenic signals diverge, 
we might be able to develop anti-angiogenic 
therapies that will more successfully treat 
cancer.  
The most obvious approach would be to 
inhibit transcription factors that up-regulate 
multiple downstream angiogenic factors. Sood’s 
proposed therapy essentially does just this, 
but in a clever way that takes advantage of an 
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Figure 1: A novel anti-
angiogenic therapy aims 
to target the trunk, not the 
branches, of this metaphorical 
tree of angiogenic mediators. 
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endogenous control mechanism to amplify the 
breadth of its effect. In humans, microRNAs 
(miRNAs) are potent negative regulators of a 
wide array of genes. miRNAs work by binding to 
the 3’ untranslated regions (3’UTRs) of specific 
mature RNA transcripts in order to prevent 
their translation to proteins. 
By correlating the expression patterns of 
many miRNAs with the degree of vascularization 
in tumor samples, Sood’s team was able to 
identify several miRNAs that were potential 
candidates for therapy. One such candidate was 
miR-192. The expression of miR-192 was found 
to correlate negatively with the expression of 
pro-angiogenic factors and angiogenesis, and 
correlate positively with patient survival.  
The next goal was to discover how exactly 
miR-192 blocks angiogenesis. Dr. Sood and 
his colleagues identified 13 potential pro-
angiogenic transcription factor targets of miR-
192. When they measured how the levels of 
these transcription factors changed in cells 
transfected with miR-192, two transcription 
factors stood out--EGR1 and HOXB9. 
To demonstrate that miR-192 impairs 
angiogenesis and tumor growth in vivo by 
blocking the translation of EGR1 and HOXB9, 
the research team devised a single elegant 
experiment. They transfected human ovarian 
cancer cells with miR-192 (or a control 
miRNA) before injecting the cells into mice. 
By monitoring tumor size, neovascularization, 
and circulating levels of EGR1 and HOXB9 
as well as those angiogenic paracrine factors 
downstream of EGR1 and HOXB9, the team 
was able to show that miR-192 impaired tumor 
growth and angiogenesis, and that miR-192 
overexpression decreased the expression of 
EGR1 and HOXB9. Superimposed on this 
experiment were additional studies in which 
miR-192 was transfected into cancer cells along 
with copies of the EGR1 and HOXB9 gene that 
lacked normal 3’UTRs. This rendered the EGR1 
and HOXB9 transcripts effectively immune to 
miR-192 and prevented miR-192 from impairing 
tumor growth or angiogenesis, demonstrating 
that EGR1 and HOXB9 are both necessary and 
sufficient to account for the anti-angiogenic 
effect of miR-192.  
The highpoint of this landmark publication 
was to show that exogenous treatment with miR-
192 could serve as a viable and effective therapy 
in a murine model of ovarian cancer. The team 
found that injecting nanoliposomes (DOPC) 
filled with miR-192 into mice recapitulated 
the anti-angiogenic effect and blocked tumor 
development by over 90% (p<0.0001), without 
any observable toxic side-effects. What’s more, 
when DOPC miR-192 therapy was compared 
to treatment with an antibody against VEGF, 
the most studied angiogenic factor and most 
Figure 2: microRNAs (miRs) 
are endogenously expressed 
noncoding RNAs that knock 
down the expression of target 
messenger RNAs (mRNAs) by 
silencing them before they can 
be translated.
Source: Wikimedia Commons 
(Credit: Narayanese)
Figure 3: Nanoparticles 
made out of amphipathic 
phospholipds allow the 
delivery of exogenous miRs 
into tumor tissue.
Source: Wikimedia Commons 
(Credit: Jesse)
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“It remains to 
be determined 
whether or not 
tumors can adapt 
to miR-192 therapy 
as they do to other 
anti-angiogenic 
therapies.”
common modern target of anti-angiogenic 
therapies, the DOPC treatment proved far more 
effective at inhibiting tumor growth over the 
course of three weeks (p<0.0001) (Hanahan and 
Weinberg, 2000; Casanovas et al., 2005; Kopetz 
et al., 2010). 
Conclusion
Although the future of miR-192 therapy 
appears promising, certain critical questions 
remain. First, it remains to be determined 
whether or not tumors can adapt to miR-192 
therapy as they do to other anti-angiogenic 
therapies. Since miR-192 blocks at least two 
transcription factors that each block substantial 
and distinct arrays of angiogenic factors, it is 
possible that miR-192 treatment might be the 
first anti-angiogenic therapy that tumors cannot 
effectively circumnavigate. Second, there is some 
indication that miR-192 treatment may serve a 
more complex role in preventing tumorigenesis. 
miR-192 is a positive regulator of the tumor 
suppressor protein p53, and loss-of-function 
mutations in this gene are known to occur 
in more than half of all cancers (Moore et al., 
2015; Lodish, 2000). Therefore, miR-192 therapy 
could in theory increase the robustness of the 
p53 DNA damage response, which may affect 
tumor development and growth. Moreover, p53 
is a positive regulator of the potent endogenous 
anti-angiogenic Thrombospondin-1, adding yet 
another layer of complexity to the potential 
anti-angiogenic benefits of miR-192 treatment.   
miRNA cancer therapy represents an 
innovative and exciting new approach for 
preventing angiogenesis and tumor growth 
and/or metastasis. Whatever the caveats and the 
unknowns, the work performed by Dr. Sood and 
his team suggests that we shift our focus from 
chopping at branches and try chopping at the 
trunk.  
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Figure 4: Certain tumors rely 
more on angiogenesis than 
others. Ovarian and kidney 
tumors rely heavily on the 
development of new blood 
vessels and were studied in 
this paper.
Source: Wikimedia Commons 
(Credit: James Heilman, MD)
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